Ultraviolet A1 phototherapy

British Journal of Dermatology

Volumn 148, Issue 4, 2003, Pages 626-637

  Dawe, Robert S ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Atopic dermatitis; Localized scleroderma; Phototherapy; Polymorphic light eruption; Systemic lupus erythematosus; Ultraviolet A1

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; FLUOCORTOLONE; IDARUBICIN;

ATOPIC DERMATITIS; CLINICAL TRIAL; GRANULOMA ANNULARE; HAND DISEASE; HUMAN; KELOID; LICHEN SCLEROSUS ET ATROPHICUS; PARAPROTEINEMIA; PHOTOTHERAPY; PITYRIASIS RUBRA PILARIS; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SCLERODERMA; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T CELL LYMPHOMA; ULTRAVIOLET A RADIATION;

CONTROLLED CLINICAL TRIALS; DERMATITIS, ATOPIC; HUMANS; RADIATION INJURIES; SCLERODERMA, LOCALIZED; SKIN DISEASES; ULTRAVIOLET THERAPY;

EID: 0037903329     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2003.05261.x     Document Type: Review

References (85)

1. Mutzhas MF, Hölzle E, Hoffmann C, Plewig G. A new apparatus with high radiation energy between 320 and 460 nm: physical description and dermatological applications. J Invest Dermatol 1981; 76: 42-7.
2. Krutmann J, Czech W, Diepgen T et al. High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol 1992; 26: 225-30.
3. Krutmann J, Schöpf E. High-dose-UVA1 phototherapy: a novel and highly effective approach for the treatment of acute exacerbation of atopic dermatitis. Acta Derm Venereol (Stockh) 1992; 176 (Suppl.): 120-2.
4. Meffert H, Sönnichsen N, Herzog M, Hutschenreuther A. Prüfung des therapeutischen Nutzens der UVA-1-Kaltlichttherapie beim akut exazerbierten, schweren atopischen Ekzem. Dermatol Monatsschr 1992; 178: 291-6.
5. Godar DE. UVA1 radiation triggers two different final apoptotic pathways. J Invest Dermatol 1999; 112: 3-12.
6. von Kobyletzki G, Heine O, Stephan H et al. UVA1 irradiation induces deoxyribonuclease dependent apoptosis in cutaneous T-cell lymphoma in vivo. Photodermatol Photoimmunol Photomed 2000; 16: 271-7.
7. Grabbe J, Welker P, Humke S et al. High-dose ultraviolet A1 (UVA1), but not UVA/UVB therapy, decreases IgE-binding cells in lesional skin of patients with atopic eczema. J Invest Dermatol 1996; 107: 419-22.
8. Petersen MJ, Hansen C, Craig S. Ultraviolet A irradiation stimulates collagenase production in cultured human fibroblasts. J Invest Dermatol 1992; 99: 440-4.
9. Stege H, Berneburg M, Humke S et al. High-dose UVA1 radiation therapy for localized scleroderma. J Am Acad Dermatol 1997; 36: 938-44.
10. Rücker BU, Häberle M, Koch HU et al. Ultraviolet light hardening in polymorphous light eruption - a controlled study comparing different emission spectra. Photodermatol Photoimmunol Photomed 1991; 8: 73-8.
11. Krutmann J, Diepgen TL, Luger TA et al. High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. J Am Acad Dermatol 1998; 38: 589-93.
12. von Kobyletzki G, Freitag M, Herde M et al. Phototherapie bei schwerer atopischer Dermatitis: vergleich zwischen herkömmlicher UVA1-Therapie, UVA1-Kaltlicht- und kombinierter UVA-UVB-Therapie. Hautarzt 1999; 50: 27-33.
13. von Kobyletzki G, Pieck C, Hoffmann K et al. Medium-dose UVA1 cold-light phototherapy in the treatment of severe atopic dermatitis. J Am Acad Dermatol 1999; 41: 931-7.
14. Dittmar HC, Pflieger D, Schöpf E, Simon JC. UVA1-Phototherapie. Pilotstudie zur Dosisfindung bei der akut exazerbierten atopischen Dermatitis. Hautarzt 2001; 52: 423-7.
15. Dittmar HC, Pflieger D, Schöpf E, Simon JC. UVA1 therapy dose-finding study in patients with acute exacerbated atopic dermatitis. Int Arch Allergy Immunol 2001; 124: 386-8.
16. Jekler J, Larkö O. Phototherapy for atopic dermatitis with ultraviolet A (UVA), low-dose UVB and combined UVA and UVB: two paired-comparison studies. Photodermatol Photoimmunol Photomed 1991; 8: 151-6.
17. Tzaneva S, Seeber A, Schwaiger M et al. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol 2001; 45: 503-7.
18. McGrath H Jr, Martínez-Osuna P, Lee FA. Ultraviolet-A1 (340-400 nm) irradiation therapy in systemic lupus erythematosus. Lupus 1996; 54: 269-74.
19. Polderman MC, Huizinga TW, Le Cessie S, Pavel S. UVA-1 cold light treatment of SLE: a double blind, placebo controlled crossover trial. Ann Rheum Dis 2001; 60: 112-15.
20. Costa C, Rilliet A, Nicolet M, Saurat JH. Scoring atopic dermatitis: the simpler the better? Acta Derm Venereol (Stockh) 1989; 69: 41-5.
21. Kowalzick L, Kleinheinz A, Weichenthal M et al. Low dose versus medium dose UV-A1 treatment in severe atopic eczema. Acta Derm Venereol (Stockh) 1995; 75: 43-5.
22. Abeck D, Schmidt T, Fesq H et al. Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis. J Am Acad Dermatol 2000; 42: 254-7.
23. European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1993; 186: 23-31.
24. Krutmann J. Phototherapy for atopic dermatitis. Clin Exp Dermatol 2000; 25: 552-8.
25. Reynolds NJ, Franklin V, Gray JC et al. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet 2001; 357: 2012-16.
26. Lehmann P, Hölzle E, Kind P et al. Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol 1990; 22: 181-7.
27. McGrath H Jr, Bak E, Michalski JP. Ultraviolet-A light prolongs survival and improves immune function in (New Zealand black x New Zealand white) F1 hybrid mice. Arthritis Rheum 1987; 30: 557-61.
28. McGrath H Jr. Ultraviolet-A1 irradiation decreases clinical disease activity and autoantibodies in patients with systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12: 129-35.
29. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
30. Sönnichsen N, Meffert H, Kunzelmann V, Audring H. UV-A-1-Therapie bei subakut-kutanem lupus erythematodes. Hautarzt 1993; 44: 723-5.
31. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-18.
32. Kerscher M, Dirschka T, Volkenandt M. Treatment of localised scleroderma by UVA1 phototherapy. Lancet 1995; 346: 1166.
33. Gruss C, Reed JA, Altmeyer P et al. Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblasts. Lancet 1997; 350: 1295-6.
34. Kerscher M, Volkenandt M, Gruss C et al. Low-dose UVA1 phototherapy for treatment of localized scleroderma. J Am Acad Dermatol 1998; 38: 21-6.
35. Gruss CJ, von Kobyletzki G, Behrens-Williams SC et al. Effects of low dose ultraviolet A-1 phototherapy on morphea. Photodermatol Photoimmunol Photomed 2001; 17: 149-55.
36. Gruss C, Stucker M, von Kobyletzki G et al. Low dose UVA1 phototherapy in disabling pansclerotic morphoea of childhood. Br J Dermatol 1997; 136: 293-4.
37. Kreuter A, Gambichler T, Avermaete A et al. Combined treatment with calcipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea. Pediatr Dermatol 2001; 18: 241-5.
38. Kerscher M, Volkenandt M, Meurer M et al. Treatment of localised scleroderma with PUVA bath photochemotherapy. Lancet 1994; 343: 1233.
39. Scharffetter-Kochanek K, Goldermann R, Lehmann P et al. PUVA therapy in disabling pansclerotic morphoea of children. Br J Dermatol 1995; 132: 830-1.
40. Steger JW, Matthews JH. UVA therapy for scleroderma. J Am Acad Dermatol 1999; 40: 787-8.
41. El-Mofty M, Zaher H, Bosseila M et al. Low-dose broad-band UVA in morphea using a new method for evaluation. Photodermatol Photoimmunol Photomed 2000; 16: 43-9.
42. Salomon N, Messer G, Dick D et al. Phototesting for polymorphic light eruption (PLE) with consecutive UVA1/UVB-irradiation. Photodermatol Photoimmunol Photomed 1997; 13: 72-4.
43. Murphy GM, Logan KA, Lovell CR et al. Prophylactic PUVA and UVB therapy in polymorphic light eruption - a controlled trial. Br J Dermatol 1987; 116: 531-8.
44. Bilsland D, George SA, Gibbs NK et al. A comparison of narrow band phototherapy (TL-01) and photochemotherapy (PUVA) in the management of polymorphic light eruption. Br J Dermatol 1993; 129: 708-12.
45. von Kobyletzki G, Dirschka T, Freitag M et al. Ultraviolet-A1 phototherapy improves the status of the skin in cutaneous T-cell lymphoma. Br J Dermatol 1999; 140: 768-9.
46. Plettenberg H, Stege H, Megahed M et al. Ultraviolet, A1 (340-400 nm) phototherapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1999; 41: 47-50.
47. Zane C, Leali C, Airo P et al. UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides. J Am Acad Dermatol 2001; 44: 629-33.
48. Plettenberg H, Stege H, Megahed M et al. UVA-1 phototherapy versus PUVA photochemotherapy in the treatment of patients with cutaneous T cell lymphoma. Photodermatol Photoimmunol Photomed 2001; 17: 87 (Abstr.).
49. Krutmann J, Stege H, Morita A, Ultraviolet-A1 phototherapy: indications and mode of action. Chapter 13. In: Dermatological Phototherapy and Photodiagnostic Methods (Krutmann J, Hönigsmann H, Elmets CA, Bergstresser PR, eds). Berlin: Springer-Verlag, 2001; 261-76.
50. Hofer A, Cerroni L, Kerl H, Wolf P. Narrowband (311-nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides. Arch Dermatol 1999; 135: 1377-80.
51. Clark C, Dawe RS, Evans AT et al. Narrowband TL-01 phototherapy for patch-stage mycosis fungoides. Arch Dermatol 2000; 136: 748-52.
52. Gathers RC, Scherschun L, Malick F et al. Narrowband UVB phototherapy for early-stage mycosis fungoides. J Am Acad Dermatol 2002; 47: 191-7.
53. von Kobyletzki G, Kreuter JA, Nordmeier R et al. Treatment of idiopathic mucinosis follicularis with UVA1 cold light phototherapy. Dermatology 2001; 201: 76-7.
54. Stege H, Schöpf E, Ruzicka T, Krutmann J. High-dose UVA1 for urticaria pigmentosa. Lancet 1996; 347: 64.
55. Stege H, Budde M, Kürten V et al. Induction of apoptosis in skin-infiltrating mast cells by high-dose ultraviolet-A-1 (UVA-1) radiation phototherapy in patients with urticaria pigmentosa. J Invest Dermatol 1999; 112: 561 (Abstr.).
56. Kowalzick L, Holig O, Waldmann T et al. Versagen von Mitteldosis- und Hochdosis-UV-A1 bei zwei Fällen von Urticaria pigmentosa. Akt Dermatol 1999; 25: 389-91.
57. Plötz SG, Abeck D, Seitzer U et al. UVA1 for hypereosinophilic syndrome. Acta Derm Venereol (Stockh) 2000; 80: 221.
58. Schmidt T, Abeck D, Boeck K et al. UVA1 irradiation is effective in treatment of chronic vesicular dyshidrotic hand eczema. Acta Derm Venereol (Stockh) 1998; 78: 318-19.
59. Peñas PF, Jones-Caballero M, Aragüés M et al. Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients. Arch Dermatol 2002; 138: 924-34.
60. Sullivan KM, Witherspoon RP, Storb R et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988; 72: 546-54.
61. Grundmann-Kollmann M, Behrens S, Gruss C et al. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. J Am Acad Dermatol 2000; 42: 134-6.
62. Stander H, Schiller M, Schwarz T. UVA1 therapy for sclerodermic graft-versus-host disease of the skin. J Am Acad Dermatol 2002; 46: 799-800.
63. Behrens S, Reuther T, von Kobyletzki G et al. Bleomycin-induzierte PSS-artige Pseudosklerodermie. Fallbericht und Revision der Literatur. Hautarzt 1998; 49: 725-9.
64. Schaller M, Romiti R, Wollenberg A et al. Improvement of cutaneous manifestations in POEMS syndrome after UVA1 phototherapy. J Am Acad Dermatol 2001; 45: 969-70.
65. Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch Dermatol 2002; 138: 99-105.
66. von Kobyletzki G, Uhle A, Pieck C et al. Acrosclerosis in patients with systemic sclerosis responds to low-dose UV-A1 phototherapy. Arch Dermatol 2000; 136: 275-6.
67. Morita A, Kobayashi K, Isomura I et al. Ultraviolet A1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dermatol 2000; 43: 670-4.
68. Kreuter A, von Kobyletzki G, Happe M et al. UVA1-Phototherapie bei Lichen sclerosus et atrophicus. Hautarzt 2001; 52: 878-81.
69. Kreuter A, Gambichler T, Avermaete A et al. Low-dose ultraviolet A1 phototherapy for extragenital lichen sclerosus: results of a preliminary study. J Am Acad Dermatol 2002; 46: 251-5.
70. Asawanonda P, Khoo LS, Fitzpatrick TB, Taylor CR. UV-A1 for keloid. Arch Dermatol 1999; 135: 348-9.
71. Hannuksela-Svahn A, Grandal OJ, Thorstensen T, Christensen OB. UVA1 for treatment of keloids. Acta Derm Venereol (Stockh) 1999; 79: 490.
72. Kowalzick L, Suckow M, Waldmann T, Pönnighaus J-M. Mitteldosis-UV-A1 versus UV-B-Therapie bei Psoriasis. Z Dermatol 1999; 185: 92-4.
73. Stern RS, Mills DK, Krell K et al. HIV-positive patients differ from HIV-negative patients in indications for and type of UV therapy used. J Am Acad Dermatol 1998; 39: 48-55.
74. Beer JZ, Olvey KM, Lee W, Zmudzka BZ. Reassessment of the differential effects of ultraviolet and ionizing radiation on HIV promoter: the use of cell survival as the basis for comparisons. Photochem Photobiol 1994; 59: 643-9.
75. Calzavara Pinton P, Capezzera R, Zane C, De Panifilis G. Medium-dose ultraviolet A1 therapy for pityriasis lichenoides et varioliformis acuta and pityriasis lichenoides chronica. J Am Acad Dermatol 2002; 47: 410-14.
76. Herbst RA, Vogelbruch M, Ehnis A et al. Combined ultraviolet A1 radiation and acitretin therapy as a treatment option for pityriasis rubra pilaris. Br J Dermatol 2000; 142: 574-5.
77. Muchenberger S, Schöpf E, Simon JC. Phototherapy with UV-A-I for generalized granuloma annulare. Arch Dermatol 1997; 133: 1605.
78. Graefe T, Konrad H, Barta U et al. Successful ultraviolet A1 treatment of cutaneous sarcoidosis. Br J Dermatol 2001; 145: 354-5.
79. Margolis-Nunno H, Robinson R, Horowitz B et al. Psoralen-mediated virus photoinactivation in platelet concentrates: enhanced specificity of virus kill in the absence of shorter UVA wavelengths. Photochem Photobiol 1995; 62: 917-22.
80. Margolis-Nunno H, Bardossy L, Robinson R et al. Psoralen-mediated photodecontamination of platelet concentrates: inactivation of cell-free and cell-associated forms of human immunodeficiency virus and assessment of platelet function in vivo. Transfusion 1997; 37: 889-95.
81. Krutman J. Therapeutic photomedicine: phototheropy. In: Fitzpatrick's Dermatology in General Medicine (Freedberg IM, Eison AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB, eds), 5th edn. New York.: McGraw-Hill, 1999; 2870-9.
82. Wallenfang K, Stadler R. Assoziation zwischen UVA1 bzw. Bade-PUVA-Bestrahlung und Melanomentwicklung? Hautarzt 2001; 52: 705-7.
83. Wang SQ, Setlow R, Berwick M et al. Ultraviolet A and melanoma: a review. J Am Acad Dermatol 2001; 44: 837-46.
84. Sterenborg HJ, van der Leun JC. Tumorigenesis by a long wavelength UV-A source. Photochem Photobiol 1990; 51: 325-30.
85. Runger TM. Role of UVA in the pathogenesis of melanoma and non-melanoma skin cancer. A short review. Photodermatol Photoimmunol Photomed 1999; 15: 212-16.